Epigenetic modulation of gene expression of human leukemia cell lines - Induction of cell death and senescence

Neoplasma

Volumn 58, Issue 1, 2011, Pages 35-44

  Elknerova, K ^a   Myslivcova, D ^a   Lacinova, Z ^a   Marinov, I ^a   Uherkova, L ^a   Stockbauer P ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

Author keywords

Apoptosis; Histone deacetylase inhibitors (HDACi) suberoylanilide hydroxamic acid (SAHA); Senescence; Valproic acid (VPA)

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; VALPROIC ACID; VORINOSTAT; ANTINEOPLASTIC AGENT; HYDROXAMIC ACID;

APOPTOSIS; ARTICLE; CELL AGING; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL STRESS; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; EPIGENETICS; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; INCUBATION TIME; LEUKEMIA CELL LINE; OPTIMAL DRUG DOSE; PHENOTYPE; SENESCENCE; CELL CYCLE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL AGING; CELL CYCLE; CELL LINE, TUMOR; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, LEUKEMIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; VALPROIC ACID;

EID: 79961110597     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: 10.4149/neo_2011_01_35     Document Type: Article

References (40)

1. MEHNERT JM. Histone deacetylase inhibitors: biology and mechanism of action. The Cancer Journal 2007, 13: 23-29. doi:10.1097/PPO.0b013e31803c72ba.
2. MINUCCI S, PELICCI PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat rev Cancer 2006, 6: 38-51. doi:10.1038/nrc1779.
3. STRAHL BD, ALLIS CD. The language of covalent histone modifications. Nature 2000, 403: 41-45. doi:10.1038/47412.
4. STRUHL K. Histone acetylation and transcriptional regulatory mechanismus. Genes Dev. 1998, 12: 599-606. doi:10.1101/gad.12.5.599.
5. CLAUS R, LUBBERT M. Epigenetic target in hematopoietic malignancies. Oncogene 2003, 22: 6489-6496. doi:10.1038/sj.onc.1206814.
6. KELLY WK, MARKS PA. Drug insight: histone deacetylase inhibitorsdevelopment of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005, 2: 150: 157.
7. VIGUSHIN DM, COOMBES. Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs. 2002, 12: 599-606.
8. MARKS PA, RICHON VM, BRESLOW R, RIFKIND RA. Histone deacetylase inhibitors as a new cancer drugs. Curr Opin Oncol. 2001, 13: 477-483. doi:10.1097/00001622-200111000-00010.
9. MARKS PA, RICHON VM, RIFKIND RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst. 2000, 92: 1210-1216. doi:10.1093/jnci/92.15.1210.
10. ROMANSKIOMANSKI A, BASIC B. Use a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia. Haematologica. 2004, 89: 419-426.
11. KNEFER R, HOFER MD, ALTUG V, ZORN C, GENZE F, et al. Sodium butyrate and tributyrin induce in vivo growth inhibition and apoptosis in human prostate cancer. Br J Cancer. 2004, 90: 535-541. doi:10.1038/sj.bjc.6601510.
12. KIM YB, KI SW, YOSHIDA M, HORINOUCHI S. Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. J Antibiot (Tokyo). 2000, 53: 1191-1200.
13. SANDOR V, BAKKE S, ROBEY RW, KANG MH, BLAGOSKLONNY MV, et al. Phase I. trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patiens with refractory neoplasms. Clin Cancer Res. 2002, 8: 718-728.
14. MARKS PA, RIFKIND RA. Histone deacetylases and cancer: causes and therapies. Nature. 2001,1: 194-202.
15. PIEKARZ RL, ROBEY RW, ZHAN Z, KAYASTHA G, SAYAH A et al. T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance. Blood 2004, 12: 4636-4643.
16. CINATL J Jr, CINATL J, DRIEVER PH, KOTCHEKOV R, POUCKOVA P et al. Sodium valproate inhibits in vivo growth of human neuroblastoma cells. Anti-Cancer Drugs. 1997, 8: 958-963. doi:10.1097/00001813-199711000-00007.
17. OLSEN CM, MEUSSSEN-ELHOLM ET, ROSTE LS, TAUBOLL E. Antiepileptic drugs inhibits cell growth in the human breast cancer cell line MCF7. Mol Cell Endocrinol. 2004, 213: 173-179. doi:10.1016/j.mce.2003.10.032.
18. TANG R, FAUSSAT AM, MAJDAK P, PERROT JY, CHAOUI D et al. Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukaemia cells expressing P-pg and MRP1. Leukemia. 2004, 18: 1246-1251. doi:10.1038/sj.leu.2403390.
19. REBBAA A, ZHENG X, CHOU PM, MIRKIN BL. Caspase inhibition switches doxorubicin-induced apoptosis to senescence. Oncogene. 2003, 22: 2805-11. doi:10.1038/ sj.onc.1206366.
20. KIM R, EMI M, TANABE K, UCHIDA Y, ARIHIRO K. The role of apoptotic or nonapoptotic cell death in determining cellular response to anticancer treatment. Eur J Surg Oncol. 2006, 32: 269-77. doi:10.1016/j.ejso.2005.12.006.
21. Narita M, Nunez S. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 2003. 113: 703-16.
22. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell. 2005. 120: 513-22.
23. LEE BY, HAN JA, IM JS, MORRONE A, JOHUNG K et al. Senescence-associated beta-galactosidase is lysosomal beta-galactosidase. Aging Cell. 2006. 5: 187-95. doi:10.1111/j.1474-9726.2006.00199.x.
24. XUE W, ZENDER L, MIETHING C, DICKINS RA, HERNANDO E et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature. 2007; 445: 656-60. doi:10.1038/nature05529.
25. MUNRO J, BARR NI, IRELAND H, MORRISON V, PARKINSON EK. Histone deacetylase inhibitors induce a senescence-like state in human cells by a p16-dependent mechanism that is independent of a mitotic clock. Exp Cell Res. 2004; 295: 525-38. doi:10.1016/j.yexcr.2004.01.017.
26. OGRYZKO VV, HIRAI TH, RUSSANOVA VR, BARBIE DA, HOWARD BH. Human fibroblast commitment to a senescence-like state in response to histone deacetylase inhibitors is cell cycle dependent. Mol Cell Biol. 1996; 16: 5210-8.
27. DIMRI GP, LEE X, BASILE G, ACOSTA M, SCOTT GET et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc Natl Acad Sci U S A. 1995; 92: 9363-7. doi:10.1073/pnas.92.20.9363.
28. LI LC, CARROLL PR, DAHIYA R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst. 2005; 97: 103-15. doi:10.1093/jnci/dji010.
29. AHN MY, JUNG JH, NA YJ, KIM HS. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol Oncol. 2008; 108: 27-33. doi:10.1016/j.ygyno.2007.08.098.
30. KOURAKLIS G, THEOCHARIS S. Histone deacetylase inhibitors: a novel target of anticancer therapy. Oncol Rep. 2006; 15: 489-94.
31. BAKKENIST CJ, KASTAN MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003; 421: 499-506. doi:10.1038/nature01368.
32. GAYMES TJ, PADUA RA, PLA M, ORR S, OMIDVAR N et al. Histone deacetylase inhibitors (HDI) cause DNA damage in leukemia cells: a mechanism for leukemia-specific HDIdependent apoptosis? Mol Cancer Res. 2006; 4: 563-73.doi:10.1158/1541-7786.MCR-06-0111.
33. TE POELE RH, OKOROKOV AL. DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res. 2002; 62: 1876-83.
34. KAHLEM P, DORKEN B, SCHMITT CA. Cellular senescence in cancer treatment: friend or foe? J Clin Invest. 2004; 113: 169-74.
35. SHELTON DN, CHANG E, WHITTIER PS, CHOI D, FUNK WD. Microarray analysis of replicative senescence. Curr Biol. 1999; 9: 939-45.
36. REN JL, PAN JS, LU YP, SUN P, HAN J. Inflammatory signaling and cellular senescence. Cell Signal. 2009; 21: 378-83.
37. LAUBER K, BLUMENTHAL SG, WAIBEL M, WESSELBORG S. Clearance of apoptotic cells: getting rid of the corpses. Mol Cell. 2004; 14: 277-87. doi:10.1016/S1097-2765(04)00237-0.
38. SCHWARZE SR, FU VX, DESOTELLE JA, KENOWSKI ML, JARRARD DF. The identification of senescence-specific genes during the induction of senescence in prostate cancer cells. Neoplasia. 2005; 7: 816-23. doi:10.1593/neo.05250.
39. CHANG BD, BROUDE EV, DOKMANOVIC M, ZHU H, RUTH A et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 1999; 59: 3761-7.
40. SHAY JW, RONINSON IB. Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene. 2004; 23: 2919-33. doi:10.1038/sj.onc.1207518.